Xiangxue Pharmaceutical Co.,Ltd. (SHE:300147)
6.94
-0.28 (-3.88%)
Jul 15, 2026, 3:04 PM CST
Xiangxue Pharmaceutical Revenue
Xiangxue Pharmaceutical had revenue of 354.16M CNY in the quarter ending March 31, 2026, a decrease of -15.88%. This brings the company's revenue in the last twelve months to 1.53B, down -10.65% year-over-year. In the year 2025, Xiangxue Pharmaceutical had annual revenue of 1.60B, down -14.16%.
Revenue (ttm)
1.53B
Revenue Growth
-10.65%
P/S Ratio
3.12
Revenue / Employee
574.22K
Employees
2,662
Market Cap
4.77B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.60B | -263.25M | -14.16% |
| Dec 31, 2024 | 1.86B | -440.63M | -19.16% |
| Dec 31, 2023 | 2.30B | 112.22M | 5.13% |
| Jan 1, 2023 | 2.19B | -783.51M | -26.38% |
| Jan 1, 2022 | 2.97B | -101.51M | -3.30% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Suzhou Fengbei Biotech Stock | 3.61B |
| Novogene | 2.26B |
| Wuhan Hvsen Biotechnology | 1.74B |
| Hefei Lifeon Pharmaceutical | 1.55B |
| Shenzhen Weiguang Biological Products | 1.26B |
| ChemPartner PharmaTech | 1.14B |
| R&G PharmaStudies | 896.26M |
| Hangzhou Biotest Biotech | 449.50M |